简介：
Overview
This protocol outlines a semi-automated method for conducting medium- to high-throughput organoid drug screenings, utilizing automated image analysis software to quantify single-organoid drug responses. This approach aims to enhance the understanding of intratumor heterogeneity in cancer research.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Drug Screening
Background
- Organoid models are crucial for studying cancer biology and therapy responses.
- Traditional methods may not capture the complexity of tumor heterogeneity.
- Automated analysis can improve efficiency and data quality.
- This protocol aims to streamline workflows in organoid research.
Purpose of Study
- To develop a method that enhances the analysis of organoid drug responses.
- To facilitate the prediction of clinical therapy responses in cancer patients.
- To create a platform-agnostic software solution for diverse imaging instruments.
Methods Used
- Enzymatic dissociation of patient-derived tumor organoids (PDTOs).
- Use of a pipetting robot for precise liquid handling.
- Automated image analysis for quantifying drug responses.
- Drug dispensing protocols for titration and control setups.
Main Results
- The protocol successfully dissociates organoids into single cells for analysis.
- Automated workflows yield reproducible and reliable data.
- Early results indicate potential for predicting therapy responses.
- Platform-agnostic software enhances accessibility for researchers.
Conclusions
- This method provides a robust framework for organoid drug screening.
- It addresses the need for efficient analysis in cancer research.
- Future applications may lead to improved patient-specific therapies.
What are organoids?
Organoids are 3D cell cultures derived from stem cells that mimic the structure and function of organs.
How does this protocol improve drug screening?
It combines automated workflows with clinically relevant analysis, enhancing data quality and efficiency.
Can this method be used for other types of cancer?
Yes, the protocol is adaptable for various cancer types using patient-derived organoids.
What is the significance of intratumor heterogeneity?
Intratumor heterogeneity refers to the diverse cell populations within a tumor, impacting treatment responses.
Is prior experience with organoids necessary?
While helpful, the protocol is designed to be accessible to researchers with varying levels of experience.
What imaging techniques can be used?
The software is designed to be platform-agnostic, allowing use with various live-cell imaging instruments.
繁體中文
